Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 1233 - 1240 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC5607 | GSK 2837808A |
|
Potent, selective lactate dehydrogenase A (LDHA) inhibitor (IC50 values are 1.9 and 14 nM for LDHA and LDHB respectively). Inhibits lactate production in selected cancer cell lines. Reduces glucose uptake and enhances mitochondrial oxygen consumption in Snu398 hepatocellular carcinoma cells. Inhibits proliferation and induces apoptosis in Snu398 cells. Inhibits transcription of histone 2B (H2B) gene in HCT116 and NCM460 cells. Cell permeable.
|
|
| BCC5608 | TC-E 5002 |
|
Selective histone demethylase KDM2/7 subfamily inhibitor (IC<sub>50</sub> values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 <span class='symbol'>μ</span>M for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells <em>in vitro</em>.
|
|
| BCC5609 | TAK 21d |
|
Potent FAAH inhibitor; (IC50 values are 0.28 and 0.72 nM, at rat and human FAAH respectively). Displays analgesic effects in vivo models of neuropathic and inflammatory pain. Brain penetrant.
|
|
| BCC5610 | JJKK 048 |
|
Potent and selective monoacylglycerol lipase (MAGL) inhibitor (IC50 = 0.4 nM). Exhibits >13,000 and ~630-fold selectivity for MAGL over FAAH and ABHD6, respectively. Increases brain levels of 2-arachidonoylglycerol (2-AG) levels in mice in vivo. Promotes analgesia in pain models.
|
|
| BCC5611 | ML 348 |
|
Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM). Exhibits 14-fold selectivity for LYPLA1 over LYPLA2. Also selective over a panel of ~30 other serine hydrolases.
|
|
| BCC5612 | ML 349 |
|
Selective and reversible lysophospholipase 2 (LYPLA2) inhibitor (IC50 = 144 nM). Displays selectively over LYPLA1 and 20 other serine hydrolases (IC50 values are >3000 and >10,000 nM respectively).
|
|
| BCC5613 | SCH 51344 |
|
Potent MTH1 inhibitor (K<sub>d</sub> = 49 nM). Inhibits Ras-induced malignant transformation and increases <span class='symbol'>α</span>-actin promoter-driven CAT activity in Ras-transformed cells. Has no effect on Ras-induced ERK and JNK activation. Inhibits Ras-induced membrane ruffling in REF-52 fibroblasts and blocks anchorage-independent growth of Ras-transformed tumor cell lines. Also induces DNA damage in SW480 colon cancer cells.
|
|
| BCC5614 | CKI 7 dihydrochloride |
|
Casein kinase 1 (CK1) inhibitor. Also inhibits SGK, S6K1 and MSK1. Induces retinal cell differentiation from human ESCs and iPSCs in combination with SB 431542 and Y-27632.
|
|